SENS (Senseonics Holdings) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SENS Senseonics Holdings Inc SENS
60 GF Score
Price $5.03
GF Value $14.35
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Senseonics Holdings FFO per Share?

FFO per Share only applies to REITs.

SENS
60GF Score
Senseonics Holdings Inc SENS
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Senseonics Holdings (SENS) Overvalued in 2026?

Based on GuruFocus' analysis, Senseonics Holdings stock appears to be undervalued. The current stock price of $5.03 is trading 64.9% below its estimated GF Value™ of $14.35. GuruFocus considers Senseonics Holdings to be Possible Value Trap.

Key valuation signals for SENS:

  • FFO per Share:
  • GF Value™: $14.35 vs. price of $5.03 (64.9% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the SENS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Senseonics Holdings Business Description

Other Exchanges 6L60:Germany
Address 20451 Seneca Meadows Parkway, Germantown, MD, USA, 20876-7005
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
60GF Score

Get the complete analysis for SENS

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.03
Price
$14.35
GF Value